KDR
Vascular endothelial growth factor receptor 2
As of the edition of 20 October 2026, KDR (vascular endothelial growth factor receptor 2, UniProt P35968) has 69 drugs tested at it and 78 companies on the list, 25 on route A and 8 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P35968
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 54
- Disease areas
- Cancer; Digestive system; Urinary and reproductive; Pregnancy and women's health; Lungs and airways; Hormones; Skin and connective tissue; Blood and lymph
- Registered trials of its drugs
- 4,533
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 12 |
| Active | 14 |
| Went quiet | 15 |
| Stopped | 25 |
| Status not established | 3 |
| Total | 69 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Sorafenib | Marketed | Phase 4 | Ends 2027 |
| Lenvatinib | Marketed | Phase 4 | Ends 2035 |
| Rivoceranib | Active | Phase 4 | none listed |
| Catequentinib | Active | Phase 4 | none listed |
| Sunitinib | Marketed | Phase 4 | none listed |
| Regorafenib | Marketed | Phase 4 | Ends 2032 |
| Pazopanib | Marketed | Phase 4 | none listed |
| Cabozantinib | Marketed | Phase 4 | Ends 2032 |
| Axitinib | Marketed | Phase 3 | Ends 2030 |
| Nintedanib | Marketed | Phase 4 | Ends 2027 |
| Ramucirumab | Marketed | Phase 3 | Ended 2026 |
| Fruquintinib | Marketed | Phase 4 | Ends 2035 |
12 of 69 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 25 |
| Route B | 8 |
| Engaged | 37 |
| Undetermined | 8 |
| Total on the list | 78 |
The other 75 companies at KDR
In the product78 companies in all; 75 are not named here, and no score is.
See the 78 companies at KDR, ranked, with the facts behind eachRequest access. Nothing is shown until you do.